Special Issue "Molecular Mechanisms of Viral Entry"

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (30 June 2020) | Viewed by 7213

Special Issue Editor

Institute for Research in Biomedicine, Bellinzona, Switzerland
Interests: viral glycoproteins; neutralizing antibodies; viral ligands and receptors; structural virology

Special Issue Information

Dear Colleagues,

Successful viral pathogens have sustained a long-standing association with their hosts and developed extremely complex adaptations to secure their own replication and survival. To start infection, viral particles need to invade a new host cell and deliver their genetic material. Initial steps include binding to cellular host components and membrane fusion. Several scientific breakthroughs have occurred over the last decade to help us to understand the molecular mechanisms of viral entry. Emergence of genome-wide CRISPR-Cas9 screens has allowed identification of key proteins used as viral receptors, and the recent advances in cryo-electron microscopy have generated key information at the atomic level to understand protein–protein interaction and membrane fusion.

This Special Issue of Vaccines will bring together a collection of reviews and peer-reviewed articles on cutting-edge research that focuses on detailing the molecular aspects of viral entry. Importantly, this Special Issue will also address new methodologies and tools leading to these discoveries. Perspectives, review articles, and original research articles are invited from specialists working on viral glycoproteins, cellular receptors, isolation and identification of neutralizing antibodies, and the structural and molecular aspects of virus binding and membrane fusion.

Dr. Laurent Perez
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • viral glycoproteins
  • neutralizing antibodies
  • viral ligands
  • structural virology
  • membrane fusion
  • genome-wide CRISPR-Cas9 for receptor discovery

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Host Receptors of Influenza Viruses and Coronaviruses—Molecular Mechanisms of Recognition
Vaccines 2020, 8(4), 587; https://doi.org/10.3390/vaccines8040587 - 06 Oct 2020
Cited by 9 | Viewed by 7041
Among the four genera of influenza viruses (IVs) and the four genera of coronaviruses (CoVs), zoonotic αIV and βCoV have occasionally caused airborne epidemic outbreaks in humans, who are immunologically naïve, and the outbreaks have resulted in high fatality rates as well as [...] Read more.
Among the four genera of influenza viruses (IVs) and the four genera of coronaviruses (CoVs), zoonotic αIV and βCoV have occasionally caused airborne epidemic outbreaks in humans, who are immunologically naïve, and the outbreaks have resulted in high fatality rates as well as social and economic disruption and losses. The most devasting influenza A virus (IAV) in αIV, pandemic H1N1 in 1918, which caused at least 40 million deaths from about 500 million cases of infection, was the first recorded emergence of IAVs in humans. Usually, a novel human-adapted virus replaces the preexisting human-adapted virus. Interestingly, two IAV subtypes, A/H3N2/1968 and A/H1N1/2009 variants, and two lineages of influenza B viruses (IBV) in βIV, B/Yamagata and B/Victoria lineage-like viruses, remain seasonally detectable in humans. Both influenza C viruses (ICVs) in γIV and four human CoVs, HCoV-229E and HCoV-NL63 in αCoV and HCoV-OC43 and HCoV-HKU1 in βCoV, usually cause mild respiratory infections. Much attention has been given to CoVs since the global epidemic outbreaks of βSARS-CoV in 2002–2004 and βMERS-CoV from 2012 to present. βSARS-CoV-2, which is causing the ongoing COVID-19 pandemic that has resulted in 890,392 deaths from about 27 million cases of infection as of 8 September 2020, has provoked worldwide investigations of CoVs. With the aim of developing efficient strategies for controlling virus outbreaks and recurrences of seasonal virus variants, here we overview the structures, diversities, host ranges and host receptors of all IVs and CoVs and critically review current knowledge of receptor binding specificity of spike glycoproteins, which mediates infection, of IVs and of zoonotic, pandemic and seasonal CoVs. Full article
(This article belongs to the Special Issue Molecular Mechanisms of Viral Entry)
Show Figures

Figure 1

Back to TopTop